Genetic and biomarker insightssuch as those from PlexusDx's Precision Peptide Genetic Testcomplement medication storage vigilance by revealing your biological predispositions in GLP-1 pathways
35 It has improved steatosis, insulin resistance, and liver stiffness in short-term trials and is actively under clinical investigation as a treatment for MASH
1 University of Padova, Padova, Italy, 2 University Hospital of Padua, Padova, Italy, 3 SantAnna School of Advanced Studies, Pisa, Italy, 4 Department of Medicine, University of Padova, Padova, Italy, 5 University of Pisa, Pisa, Italy
Although severe TEAEs were infrequent overall, they increased with treatment intensity: 2% in the semaglutide group, 1.4% in the low-dose combination, 3.3% in the high-dose combination, and 10.1% in the triplet therapy arm
Digestive issues like diarrhea, constipation, and abdominal discomfort are common